# Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)

> **NCT04812379** · — · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 535 (actual)

## Conditions studied

- Bipolar Disorder I

## Interventions

- **DRUG:** Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)

## Key facts

- **NCT ID:** NCT04812379
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2023-09-13
- **Final completion:** 2024-06-21
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812379, "Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04812379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*